Want to join the conversation?
$BIIB 2Q15 Call: In July 2015, BIIB presented additional interim aducanumab Phase 1b study at the Alzheimer’s Association International Conference. Finalized the aducanumab Phase 3 study design; program will be conducted globally and will include more than 300 sites. Obtained Phase 2 study results for TYSABRI.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.
$SPY can the rally continue? La Pen almost assured to lose makes me cautious about the results, not a place to panic. If 2400 is reached I'm selling my puts and going for broke. Happy hunting.